Sylvester Comprehensive Cancer Center

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    		SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue
    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study
    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200056 - D'Amato Gina

  • Investigator:
    Gina D'Amato
    RCname Email

    		Coordinator:
    RCemailImg Nailet Real Bestard
    RCphone +1 (305) 2438173

    IRB: 20200056

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Anus,Bladder,Bones and Joints,Breast,Cervix Uteri,Colon,Esophagus,Kidney,Lip, Oral Cavity and Pharynx,Liver,Lung,Melanoma, skin,Other Digestive Organ,Other Urinary,Ovary,Prostate,Rectum,Small Intestine,Soft Tissue,Stomach,Thyroid
    Sponsor: DECIPHERA

    Enrolling Sites:

    Sylvester
    Title:

    A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor
    Eligibility Criteria - NCT03069469 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    		Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    		SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue
    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester
    Title:

    Molecular Analysis for Therapy Choice (MATCH)
    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue
    Sponsor: CP

    Enrolling Sites:

    Sylvester
    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers
    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • RTX-240-01 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20200686

    		SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Multiple
    Sponsor: Rubius Therapeutics

    Enrolling Sites:

    Sylvester
    Title:

    PHASE 1/2 STUDY OF RTX-240 AS A MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB
    Eligibility Criteria - NCT04372706 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210890 - Merchan Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    		Coordinator:
    RCemailImg Isabel Fernandez
    RCphone +1 (305) 2435486

    IRB: 20210890

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon
    Sponsor: Exelixis Pharmaceuticals

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester
    Title:

    A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects With Inoperable Locally Advanced or Metastatic Solid Tumors
    Eligibility Criteria - NCT03845166 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210470 - MINOCHA VINAY

  • Investigator:
    VINAY MINOCHA
    RCname Email

    		Coordinator:
    RCemailImg Carla Montoya

    IRB: 20210470

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon,Rectum
    Sponsor: Mirati

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy
    Eligibility Criteria - NCT04793958 *This information has been extracted from " www.clinicaltrials.gov"

  • Tbio-6517-ITu-001 - Pimentel, Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20200277

    		SDG: Colorectal Cancer
    Disease Site(s):

    Multiple
    Sponsor: TSB

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1/2a, Multicenter, Open-label Trial of TBio-6517, an Oncolytic Vaccinia Virus, Administered Alone and in Combination with Pembrolizumab, in Patients with Advanced Solid Tumors
    Eligibility Criteria - NCT04301011 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210855 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:
    RCemailImg Siudy Vasquez Escobar
    RCphone +1 (305) 2432122 x62122

    IRB: 20210855

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon,Rectum
    Sponsor: PFIZER

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF FIRST-LINE ENCORAFENIB PLUS CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY VERSUS STANDARD OF CARE THERAPY WITH A SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB PLUS CHEMOTHERAPY IN PARTICIPANTS WITH METASTATIC BRAF V600E-MUTANT COLORECTAL CANCER
    Eligibility Criteria - NCT04607421 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211061 - Pimentel Agustin

  • Investigator:
    Agustin Pimentel
    RCname Email

    		Coordinator:

    IRB: 20211061

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon
    Sponsor: BRISTOL-MYERS SQUIBB

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    Title:

    A Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Metastatic Colorectal Cancers
    Eligibility Criteria - NCT03377361 *This information has been extracted from " www.clinicaltrials.gov"

  • DECREASE - Portelance, Lorraine

  • Investigator:
    Lorraine Portelance
    RCname Email

    		Coordinator:
    RCemailImg Samantha St. Armand

    IRB: 20191276

    		SDG: Colorectal Cancer
    Disease Site(s):

    Anus
    Sponsor: ECOG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester
    Title:

    A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)
    Eligibility Criteria - NCT04166318 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    		Coordinator:

    IRB: 20160656

    		SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic
    Sponsor: AMC

    Enrolling Sites:

    Sylvester
    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors
    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • RPL-001-16 - Rodriguez, Estelamari

  • Investigator:
    Estelamari Rodriguez
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20180802

    		SDG: Bone and Soft Tissue Cancers
    Disease Site(s):

    Bladder,Breast-Female,Colon,Melanoma, skin
    Sponsor: REPLIMUNE

    Enrolling Sites:

    Sylvester
    Title:

    RPL-001-16: An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors
    Eligibility Criteria - NCT03767348 *This information has been extracted from " www.clinicaltrials.gov"

  • Anchor Study - Rosa-cunha, Isabella

  • Investigator:
    Isabella Rosa-cunha
    RCname Email

    		Coordinator:

    IRB: 20160316

    		SDG: Population Sciences
    Disease Site(s):

    Anus
    Sponsor: AMC

    Enrolling Sites:

    JMH
    Sylvester
    Title:

    ANCHOR: Anal Cancer Prevention StudyAnal Cancer/HSIL Outcomes Research Study
    Eligibility Criteria - NCT02135419 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210943 - Sussman Daniel

  • Investigator:
    Daniel Sussman
    RCname Email

    		Coordinator:

    IRB: 20210943

    		SDG: Colorectal Cancer
    Disease Site(s):

    Colon
    Sponsor: Janssen

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1b Study to Evaluate the Efficacy and Safety of JNJ-64251330, a Janus Kinase (JAK) Inhibitor, in Participants with Familial Adenomatous Polyposis
    Eligibility Criteria - NCT05014360 *This information has been extracted from " www.clinicaltrials.gov"

  • SPN-00714 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20190673

    		SDG: Other
    Disease Site(s):

    Breast,Colon,Esophagus,Kidney,Lung,Other Female Genital,Ovary,Stomach
    Sponsor: MTEM

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
    Eligibility Criteria - NCT04029922 *This information has been extracted from " www.clinicaltrials.gov"

  • ATRC-101-A01 - Valdes, Frances

  • Investigator:
    Frances Valdes
    RCname Email

    		Coordinator:
    RCemailImg Yanel Diaz Caro
    RCphone 3052438227

    IRB: 20200938

    		SDG: Other
    Disease Site(s):

    Breast,Colon,Lung,Melanoma, skin,Ovary
    Sponsor: Atreca Inc

    Enrolling Sites:

    Sylvester
    Title:

    A Phase 1b Dose Escalation Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATRC-101 as Monotherapy and in Combination with Other Anticancer Agents in Adults with Advanced Solid Malignancies
    Eligibility Criteria - NCT04244552 *This information has been extracted from " www.clinicaltrials.gov"